Provectus Biopharmaceuticals to Present Immunology Data on PV-10 in Colon Cancer at 11th Annual ASC Meeting

Pharmaceutical Investing

Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT) announced will be presenting an abstract discussing the immunologic effects of PV-10 on colon cancer cells at the 11th Annual Academic Surgical Congress to be held February 2-4, 2016, at the Hyatt Regency in Jacksonville, Florida.

Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT) announced will be presenting an abstract discussing the immunologic effects of PV-10 on colon cancer cells at the 11^th Annual Academic Surgical Congress to be held February 2-4, 2016, at the Hyatt Regency in Jacksonville, Florida.

According to the company press release:

The abstract, titled “PV-10 Induces Potent Immunogenic Apoptosis in Colon Cancer Cells,” will be presented by Dr. A.V. Maker. It is co-authored by N. M. Kunda, J. Qin, G. Qiao working out of the University Of Illinois At Chicago, Division Of Surgical Oncology, Department Of Surgery, College Of Medicine, Chicago, IL, USA. The team of authors also includes B. Prabhakar of the University Of Illinois At Chicago, Department Of Microbiology & Immunology, College Of Medicine, Chicago, IL, USA. Dr. Maker belongs to both Departments.

Click here to view the full press release.

biopharmaceuticals cancer oncology provectus Company News